People · Operator
Named in public records as an officer, director or promoter · active 2017–2024 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Senti Biosciences, Inc. | — | Biotechnology | Series B | $77.0M | $222.0M | 2024 |
| Catalyte, Inc | — | Other Technology | Series A | $37.7M | $12.6M | 2017 |
Donald Tang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Donald Tang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Young | 1 | 16 |
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| James Collins | 1 | 8 |
| Alex Kolicich | 1 | 8 |
| Philip Lee | 1 | 4 |
| Sheila Marcelo | 1 | 4 |
| Michael Rosenbaum | 1 | 4 |
| Sarah Levy | 1 | 3 |
| Lillian Meyer | 1 | 2 |
| Timothy Lu | 1 | 2 |
| Vivek Khanna | 1 | 2 |
| Matthew Derella | 1 | 1 |
| Gregory Heard | 1 | 1 |
| Denis McDonough | 1 | 1 |
| Robert Rosenbaum | 1 | 1 |
| Jim D. Ungerleider | 1 | 1 |
| Peter M. Lee | 1 | 1 |
| Gregory D. Heard | 1 | 1 |
| Robert D. Rosenbaum | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.